Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8386320 | 0.80 | NNMT (0.46) | NNMTACHEGRM5 | |
| SCHEMBL8388284 | 0.74 | NNMT (0.49) | KDM4ENNMTACHEGRM5 | |
| SCHEMBL24765213 | 0.71 | ADRA2A (0.52) | MAOAKDM4ENNMTGRM5 | |
| SCHEMBL25068052 | 0.70 | NNMT (0.45) | NNMTGRM5 | |
| SCHEMBL12340834 | 0.69 | NNMT (0.41) | MAOAMAOBHRH3NNMTGRM5 | |
| SCHEMBL22584978 | 0.67 | KDM4E (0.49) | MAOBKDM4EHRH3 | |
| SCHEMBL5638601 | 0.67 | MAOB (0.50) | MAOAMAOBHRH3BCHEACHE | |
| SCHEMBL5637627 | 0.67 | HRH3 (0.58) | MAOAMAOBKDM4EHRH3 | |
| SCHEMBL1267580 | 0.67 | KDM4E (0.46) | MAOAMAOBKDM4E | |
| SCHEMBL1798509 | 0.66 | KDM4E (0.59) | MAOAMAOBKDM4EBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846941-B2 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | KIT, FLT3, FLT1 | MAOA 1279/4885MAOB 621/4885KDM4E 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.